FDA Classifies Vaginitis Germ Detection Device as Safe
Published Date: 8/21/2025
Rule
Summary
The FDA is officially putting a new test that spots germs causing vaginitis and bacterial vaginosis into a safer, middle-level category called Class II. This means the device will follow special safety rules, making sure it works well and is safe to use. This change helps patients get better access to these helpful tests faster, without extra red tape, and it affects companies making or selling these devices starting now.
Analyzed Economic Effects
2 provisions identified: 2 benefits, 0 costs, 0 mixed.
Vaginitis/BV Test Reclassified to Class II
The FDA has classified tests that detect nucleic acid sequences from microorganisms associated with vaginitis and bacterial vaginosis into Class II (special controls). The Agency says this classification provides a reasonable assurance of safety and effectiveness and will enhance patients' access to these tests by reducing regulatory burdens.
Reduced Regulatory Burden for Manufacturers
The FDA's reclassification of the nucleic-acid test for vaginitis and bacterial vaginosis to Class II is intended to reduce regulatory burdens on makers and sellers of these devices. The rule affects companies making or selling these devices starting now according to the order.
Personalized for You
How does this regulation affect your finances?
Personalize government policy and PRIA will tell you what this federal register document means for your household, plus every other regulation we track. PRIA reads each provision against your financial profile to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-16296, Substances Generally Recognized as Safe
The Food and Drug Administration (FDA or we) is proposing to require the submission of generally recognized as safe (GRAS) notices for the use of a human or animal food substance purported to be GRAS under the conditions of its intended use under the Federal Food, Drug, and Cosmetic Act (FD&C Act).
2026-14073, Drug Establishment Registration and Drug Listing Requirements for Establishments Engaged in Distributed Manufacturing and Certain Foreign Establishments
The FDA wants to make it easier for drug makers who work in several locations to register as one company instead of many. They’re also updating rules for foreign drug companies to match new laws about handling health threats. If you’re in drug manufacturing, get ready to comment by September 11, 2026, and keep an eye on possible paperwork changes that could affect your business.
2026-13047, Establishment Registration and Product Listing for Tobacco Products
The FDA wants to make sure all tobacco product makers, both in the U.S. and abroad, register their businesses and list their products. This new rule closes a big gap by including foreign companies, helping the FDA keep better track of tobacco products for public health. Comments on this proposal are open until September 14, 2026, so affected businesses should get ready to update their info and possibly face new costs.
2025-04978, Nonprescription Drug Product With an Additional Condition for Nonprescription Use
The FDA is delaying a new rule about nonprescription drugs that have extra conditions for use. Originally set to start on March 21, 2025, the rule’s start date is now pushed back to May 27, 2025, to allow more time for review. This affects drug makers and consumers by giving everyone extra time to prepare for the new requirements without any immediate cost changes.
2025-01840, Nonprescription Drug Product With an Additional Condition for Nonprescription Use
The FDA’s new rule about nonprescription drugs needing extra conditions before use was set to start on January 27, 2025, but it’s now delayed until March 21, 2025. This delay follows a presidential order to pause and review new rules before they take effect. Drug makers, sellers, and consumers should note the new start date and get ready for the updated rules soon.
2026-20727, Medical Devices; Immunology and Microbiology Devices; Classification of the System for Detection of Nucleic Acid From Non-Viral Microorganism(s) Causing Sexually Transmitted Infections Using Home-Collected Specimens
The FDA is officially classifying home test kits that detect non-viral germs causing sexually transmitted infections as Class II devices, meaning they have special safety rules but fewer hurdles than the strictest category. This change, effective October 9, 2026, helps make these tests safer and easier to get, benefiting patients and innovators alike. If you make or use these home test kits, this update means better access and clear safety standards without extra costs or delays.
Previous / Next Documents
Previous: 2025-16008, Rescinding Regulations on Procedures for Advance Construction of Federal-Aid Projects
The government is scrapping an old rule from 1990 about how federal money can be used early for big construction projects. This change affects anyone working on federal-aid road projects by making the process simpler and clearer. No new costs or deadlines pop up, but it clears the way for smoother project planning and funding.
Next: 2025-16031, Medical Devices; Immunology and Microbiology Devices; Classification of the Anti-Phospholipase A2 Receptor Immunological Test System
The FDA is officially putting the anti-phospholipase A2 receptor test into a special safety category called Class II. This means the test will have clear rules to keep it safe and effective, helping patients get access to this important medical tool faster. Labs and device makers should get ready for these new rules, which aim to make things smoother without extra costs or delays.